CGN Capregen

    RNS Number : 7070D
  CapRegen PLC
  18 September 2008
   

    18 September 2008
    CapRegen plc

    Two further investments

    CapRegen plc ("CapRegen" or "the Group"), the AIM listed anti-ageing and regenerative medicine investment company, is pleased to
announce that it has today made its second and third investments.

    Second Investment - CapRegen Nutraceuticals Inc ("CNI")

    CapRegen has formed a new US based company, CapRegen Nutraceuticals Inc., which will initially be owned 96% by CapRegen and 4% by CNI
staff and licensees. If agreed financial targets are achieved over the first two years of operation, the CNI staff and licensees'
shareholding can increase to 12%. CNI will sell and market nutraceutical products acquired under license from third parties to anti-ageing
doctors. CNI has entered into two third party licenses today. 

    The first two licensees have developed nutraceutical products as follows:

    *     The Natural Pharm Source LLC - have developed a suite of products including nutraceuticals for joint health and mobility,
cholesterol lowering and for digestive enzyme deficiencies.
    *     Ultimate Medical Research LLC - have developed a suite of products including: (i) a herbal product for the elimination of
oestrogen, (ii) an appetite reduction product, (iii) a fibre meal replacement product, and (iv) an intimate enhancement product.
    CNI have set up a sales and marketing operation based in California which will sell and market these products to anti-ageing doctors and
medical professionals. It is planned that CNI will enter into further license arrangements to expand its range of nutraceutical products.

    CapRegen will provide CNI with a working capital facility of up to $250,000.

    Third Investment - Natural Biosciences Inc ("NBI")

    CapRegen has acquired 50% of Natural Biosciences Inc, a U.S. company, for $250,000. NBI will initially market three medicinal mushroom
products that assist the body's immune system in its fight against illness and disease. They also have anti-oxidant and anti-inflammatory
potential. In addition, NBI plans to develop diagnostic products for the early detection of oxidation stress. NBI is also in the process of
negotiating a license for a compound that may be able to carry a potent antioxidant back and forth across cell barriers.

    NBI is a newly established company and was set up by Dr Marvin Hausman, an accomplished immunologist, surgeon and life sciences
executive. Dr Hausman will be the CEO of NBI and will use the sales and marketing services of CNI, our second investment, to sell and market
the three medicinal mushroom products to anti-ageing doctors and medical professionals.

    Dr Hausman has a long and successful track record of working in the public company arena. He was until recently Chairman and CEO of Oxis
International Inc., a US public company, which specialises in research and development of technologies and therapeutic products in the field
of oxidative stress and inflammatory reaction. He was also chairman of Axonyx, a NASDAQ company involved in the development of drugs
relating to Alzheimer's Disease and other central nervous system indications, until 2006 when it merged with Torry Pines Therapeutics. Prior
to founding Axonyx, Dr. Hausman was a co-founder of Medco Research Inc., a pharmaceutical biotechnology company specializing in adenosine
products which was subsequently acquired by King Pharmaceuticals.

    Douglas Emslie, Chairman of CapRegen said:

    "We are very pleased to have made these two new investments. CNI gives us exposure to the fast growth US nutraceutical market and
creates a platform to sell and market additional products to anti-ageing doctors. NBI have developed some interesting products and have
access to very early stage research which could, with Dr Hausman's experience and track record, prove beneficial to the Group in the medium
term."


    FOR FURTHER INFORMATION, PLEASE CONTACT: 

    Capregen plc:
    Douglas Emslie, Chairman            020 8846 2700

    Nominated Adviser: 
    Blue Oar Securities Plc
    William Vandyk                                020 7448 4400







This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCSFFFWWSASEDU

Capregen (LSE:CGN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024

Capregen (LSE:CGN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024